In a significant ruling favoring generic palyers,a German court has allowed generic launch of Clopidogrel besylate. This ruling will led Cimex AG, Schweizerhall and Novartis to launch this product in Germany and subsequently into the European market. Innovator Sanofi-Aventis and its U.S. partner Bristol-Myers Squibb announced that they would challenge a German court's decision to immediately authorize marketing of the generic versions of their blockbuster blood thinner Plavix (Clopidogrel). The generic players intend to launch this product by different salt. The approved salt is Clopidogrel bisulfate and generic will launch their product with Clopidogrel BesylateEarlier news of Ippharmadoc on this issue Here, Here, and Here
Wednesday, 30 July 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment